Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

R&D Deal Heralds New Treatments for Debilitating Conditions

By Drug Discovery Trends Editor | June 12, 2015

New treatments are on the horizon for ankylosing spondylitis and two other debilitating conditions that affect up to three per cent of the global population – thanks to a research and development deal involving University of Queensland research.

University of Queensland Diamantina Institute Director Professor Matt Brown said the agreement between UQ’s commercialisation arm, UniQuest, and Janssen Cilag Pty Limited (Janssen), would capitalise on more than a decade of research.

The research involves important enzymes involved in activating the immune system.

Professor Brown said it had implications for the treatment of ankylosing spondylitis – a painful form of arthritis – and for psoriasis and inflammatory bowel disease.

“These three conditions affect two to three per cent of the world’s population, and there is a great need for better treatments,” he said.

“This research and development agreement is a dream come true.

“I have spent my career researching the causes of these conditions, so it is tremendously rewarding to be collaborating with Janssen to find a treatment based on one of our discoveries.”

Professor Matt Brown from The University of Queensland on Vimeo available for media use.

Ankylosing spondylitis is an incurable immune disease affecting the spine, joints and tendons, and can be difficult to diagnose.

“Patients often ignore the initial symptoms, including recurring back pain and stiffness, but if untreated it can slowly worsen and result in the spine becoming fused and totally inflexible.” Professor Brown said.

Current treatments focus on reducing the symptoms, using non-steroidal anti-inflammatories and biologic therapies to minimise pain and inflammation.

In the 1970s it was discovered that most people with ankylosing spondylitis carried a mutation on a gene called HLA-B27.

Professor Brown said that for 40 years it was thought to be the only gene involved in the development of the disease.

“But since 2007 we have identified more than 26 other genes involved in the development of ankylosing spondylitis. This discovery has led to the resulting research collaboration.”

Professor Brown and colleagues published research in Nature Genetics in 2011, explaining how select enzymes work with HLA-B27 to help the immune system distinguish between what is self and what is foreign.

They showed that in ankylosing spondylitis genetic variants result in the production of overactive enzymes that act in combination with HLA-B27 to induce arthritis. 

Research published in Nature Communication last month shows that a specific enzyme works in conjunction with HLA-B27 and other genes associated with ankylosing spondylitis, psoriasis and inflammatory bowel disease.

Professor Brown said the culmination of this research led to the identification of two enzymes as promising drug targets.

“We think that by inhibiting these enzymes we could be able to switch off the immune reaction that causes these common diseases.” he said.

“In animal models the absence of such genes appears to have very few side effects.

“Our three-year collaboration seeks to capitalise on Janssen’s drug discovery expertise including their capability to screen thousands of compounds to find inhibitors of the two enzymes, which we would optimise together.”

Janssen Cilag Pty Limited, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, will have exclusive worldwide rights to develop and commercialise the drug candidates identified by UQ researchers.

Source: University of Queensland


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
A media release and Scientific Report image of Elizabeth Kellogg. - Camera Settings: ILCE-9M2, 12mm, ISO 1000, 1/80, f/3.2, Fri, 04-19-2024 at 10:10. v.12.01.23
St. Jude pioneers gene editing and structural biology to advance pediatric research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE